Skip to main content
. 2021 Jan 27;70(8):2261–2274. doi: 10.1007/s00262-021-02848-0

Fig. 1.

Fig. 1

Patient with PD-L1-negative lung squamous cell carcinoma benefiting from Pembrolizumab treatment. a Blood samples collection time point. b–d Before treatment, bronchoscopy results of left common branch; left common branch end; left upper lobe (fluorescence). e Before treatment, CT examination results. f After more than one month of treatment, CT examination results. g After two and a half months of treatment, CT examination results